Lotus Pharmaceutical announced on November 10 that its preliminary consolidated revenue for October 2025 reached NT$2.753 billion, up 46% year-on-year, marking the second-highest revenue in company history. Cumulative revenue for the first ten months of the year totaled NT$17 billion, a 6% increase over the same period last year, setting a record for the highest revenue in the same period historically.

October’s revenue surged to NT$2.753 billion, a 126.8% increase from the previous month and a 46% year-on-year growth, second only to NT$3.349 billion recorded in September 2022. The growth was primarily driven by the blood cancer drug Lenalidomide reaching its annual sales peak.

Analyzing performance by market, as of October, Lotus Pharmaceutical’s revenue in Asia increased 15% year-on-year, benefiting from strong sales in Thailand and Vietnam, with Southeast Asia revenue up 126% over the same period last year. In contrast, export markets showed a slight 3% decline compared with the same period last year. While Lenalidomide in the U.S. achieved double-digit growth, the overall export contribution was partially offset by weaker performance of other products, as well as a roughly 3% appreciation of the New Taiwan Dollar against the U.S. dollar compared with last year.

Resource: 血癌藥步年度銷售高峰，美時10月營收衝上歷史次高